Misplaced Pages

Common variable immunodeficiency
Specialty	Immunology
Symptoms	Hypogammaglobulinemia, recurrent opportunistic infections, fatigue
Complications	Autoimmune manifestations; increased risk of malignancies such as gastric carcinomas, non-Hodgkin lymphoma; lymphocytic infiltration of tissues; nodular regenerative hyperplasia; enteropathy
Usual onset	Varies; median age for symptoms is early 20s for males and mid-20s for females
Duration	Lifelong
Types	CVID1, CVID2, CVID3, CVID4, CVID5, CVID6
Causes	Uncertain; at least 30% have an identified heterogeneous gene mutation and/or inheritance of mutations
Diagnostic method	Exclusion of other possible causes of hypogammaglobulinemia
Differential diagnosis	Varies by age group Age <4: leaky SCID, transient hypogammaglobulinemia of infancy, XLP, XLA, hyper-IgM syndromes, myelodysplastic syndromes, Wiskott-Aldrich syndrome, rare combined immune deficiencies, cystic fibrosis, HIV Age 5-55: loss of immunoglobulin due to renal/gut disease; side effects of medications (particularly anticonvulsants and anti-rheumatics) Age >56: thymoma, lymphoid malignancies, side effects of medications (particularly anticonvulsants and anti-rheumatics), loss of immunoglobulin due to renal/gut disease
Treatment	Immunoglobulin replacement therapy, symptom management
Prognosis	Varies by type; recent studies suggest those with only recurrent infections have little or no reduced life expectancy post-diagnosis, while those with disease-related complications have around 50% survival rate 33 years post-diagnosis
Frequency	Less than 1 in 30,000

Common variable immunodeficiency (CVID) is an inborn immune disorder characterized by recurrent infections and low antibody levels, specifically in immunoglobulin (Ig) types IgG, IgM, and IgA. Symptoms generally include high susceptibility to pathogens, chronic lung disease, as well as inflammation and infection of the gastrointestinal tract.

CVID affects males and females equally. The condition can be found in children or teens but is generally not diagnosed or recognized until adulthood. The average age of diagnosis is between 20 and 50.

However, symptoms vary greatly between people. "Variable" refers to the heterogeneous clinical manifestations of this disorder, which include recurrent bacterial infections, increased risk for autoimmune disease and lymphoma, as well as gastrointestinal disease. CVID is a lifelong disease.

Signs and complications

The symptoms of CVID vary between those affected. Its main features are hypogammaglobulinemia and recurrent infections. Hypogammaglobulinemia manifests as a significant decrease in the levels of IgG antibodies, usually alongside IgA antibodies; IgM antibody levels are also decreased in about half of those affected.

Infectious complications

People with common variable immunodeficiency have trouble fighting off infections due to the lack of antibodies produced, which normally resist invading microbes. Infections are also the leading cause of morbidity and mortality in CVID patients. Due to impaired antibody development, vaccination is not effective for CVID patients.

The prevalence of bacterial complications (42%) is higher in comparison to viral (25%), parasitic (19%) or fungal (3%). Recurring bacterial infections are generally found in the upper and lower areas of the respiratory tract and in gastrointestinal tract. Many who have a recurring lung infection report developing chronic lung diseases and potentially life-threatening complications later in life.

Common infections include:

• Pneumonia
• Ear infections
• Sinusitis
• Chronic coughing (lasting from a few weeks to many months)
• Gastrointestinal infections

The microorganisms that most frequently cause infections in CVID are Haemophilus influenzae, Streptococcus pneumoniae, and Staphylococcus aureus. Pathogens less often isolated from those affected include Neisseria meningitidis, Pseudomonas aeruginosa, respectively Giardia lamblia, Salmonella sp., Campylobacter jejuni for gastrointestinal tract.

Infections mostly affect the respiratory tract (nose, sinuses, bronchi, lungs) and the gastrointestinal tract; they can also occur at other sites, such as the eyes, skin, and ears. These infections respond to antibiotics but can recur upon discontinuation of antibiotics. Bronchiectasis can develop when severe, recurrent pulmonary infections are left untreated.

Gastrovascular infections or inflammation are very common for those with CVID. Signs of a gastrovascular infection include abdominal pain, nausea, bloating, vomiting, diarrhea, and weight loss. Many individuals with CVID have an impaired ability to absorb nutrients, including vitamins, proteins, minerals, fats, and sugar, within the digestive tract.

Autoimmune disorders

CVID is frequently associated with a variety of autoimmune diseases. They could present as the first or the only clinical manifestation of the disease. The reported prevalence of autoimmunity ranged from 14% to 54% in CVID patients and is higher for females. The most common autoimmune disorders observed in CVID are autoimmune cytopenia, idiopathic thrombocytopenic purpura (ITP), AIHA and neutropenia. Furthermore, autoimmune endocrinological (insulin-dependent diabetes, autoimmune thyroiditis), gastrointestinal (anemia, autoimmune enteropathy), dermatological (psoriasis, vitiligo) and rheumatological disorders were described in CVID too.

The reason for such a high prevalence of autoimmunity in CVID individuals is not fully understood. CVID patients with autoimmunity show decreased number of immunosuppressive regulatory T cells (Treg) and impaired selection process of self-reactive antibodies, suggesting the possible mechanism.

Malignancy and CVID

The patients with CVID have a risk 5 to 12 times higher than the general population. The most frequent malignancies are Non-Hodgkin lymphoma (NHL), gastric carcinoma and leukemia.

Enteropathy

There is a wide spectrum of noninfectious gastrointestinal pathology and inflammation in CVID that is a part of the general immune dysregulation affecting patients with CVID.

The most common upper gastrointestinal inflammation is chronic gastritis, which may in rare cases develop to gastric cancer, and duodenal inflammation resembling celiac disease. The inflammation affecting the lower GI tract is heterogenous and often characterized as an unspecific colitis.

Recent studies have suggested a role of gut microbiota in the etiology of CVID, and the reduction of mucosal IgA in CVID enteropathy. The heterogenous group of patients makes it difficult to find common grounds for treatment for the GI inflammation in CVID.

Other complications

Due to changes in B cell development, some individuals with CVID have accumulations of lymphocytes in lymphoid tissues. This can cause mild to severely swollen lymph nodes or inflammation of the spleen.

Lymphocytic infiltration to tissues may cause enlargement of lymph nodes (lymphadenopathy), of the spleen (splenomegaly), and of the liver (hepatomegaly), as well as the formation of granulomas. In the lung, this is known as granulomatous–lymphocytic interstitial lung disease.

Anxiety and depression can occur as a result of dealing with the other symptoms.

CVID patients generally complain of severe fatigue.

Pathogenesis of CVID

Genetic defects

The causative factors of CVID are not fully known. Genetic mutations can be identified as the cause of disease in about 10% of people, while familial inheritance accounts for 10–25% of cases. Rather than arising from a single genetic mutation, CVID seems to result from a variety of mutations that all contribute to a failure in antibody production.

Mutations in the genes encoding ICOS, TACI, CD19, CD20, CD21, CD80, and BAFFR have been identified as causative of CVID. Susceptibility to CVID may also be linked to the major histocompatibility complex (MHC) of the genome, particularly to DR-DQ haplotypes. A mutation in the NFKB2 gene has recently been shown to cause CVID-like symptoms in a murine model. The frequency of this NFKB2 mutation in the CVID population is, however, yet to be established.

Epigenetic factors

Several recent studies have described a potential role of epigenetics factor (including DNA methylation, chromatin and histone modulation and also non-coding RNAs) in pathogenesis of CVID.

Immune cell abnormalities

There are several abnormalities described in CVID patients connected to the count of particular cell (sub)populations.

The majority of CVID patients have normal B cell counts, suggesting the impaired antibody production is mainly a defect in the differentiation process of B cells into memory and plasma cells.

There are also T cell abnormalities in CVID including counts, percentages, surface markers and function differences.

Diagnosis

According to a European registry study, the mean age at onset of symptoms was 26.3 years old. As per the criteria laid out by ESID (European Society for Immunodeficiencies) and PAGID (Pan-American Group for Immunodeficiency), CVID is diagnosed if:

• the person presents with a marked decrease in serum IgG levels (<4.5 g/L) and a marked decrease below the lower limit of normal for age in at least one of the isotypes IgM or IgA;
• the person is four years of age or older;
• the person lacks an antibody immune response to protein antigens or immunization.

Diagnosis is chiefly by exclusion, i.e., alternative causes of hypogammaglobulinemia, such as X-linked agammaglobulinemia, must be excluded before a diagnosis of CVID can be made.

Diagnosis is difficult because of the diversity of phenotypes seen in people with CVID. For example, serum immunoglobulin levels in people with CVID vary greatly. Generally, people can be grouped as follows: no immunoglobulin production, immunoglobulin (Ig) M production only, or both normal IgM and IgG production. Additionally, B cell numbers are also highly variable. 12% of people have no detectable B cells, 12% have reduced B cells, and 54% are within the normal range. In general, people with CVID display higher frequencies of naive B cells and lower frequencies of class-switched memory B cells. Frequencies of other B cell populations, such as IgD memory B cells, transitional B cells, and CD21 B cells, are also affected and are associated with specific disease features. Although CVID is often thought of as a serum immunoglobulin- and B cell-mediated disease, T cells can display abnormal behavior. Affected individuals typically present with low frequencies of CD4, a T-cell marker, and decreased circulation of regulatory T cells and iNKT cells. Notably, approximately 10% of people display CD4 T cell counts lower than 200 cells/mm; this particular phenotype of CVID has been named LOCID (Late Onset Combined Immunodeficiency) and has a poorer prognosis than classical CVID.

Types

The following types of CVID have been identified, and correspond to mutations in different gene segments:

Treatment

Treatment options are limited and usually include lifelong immunoglobulin replacement therapy. This therapy is thought to help reduce bacterial infections. This treatment alone is not wholly effective, and many people still experience other symptoms such as lung disease and noninfectious inflammatory symptoms. This treatment replenishes Ig subtypes that the person lacks, is given at frequent intervals for life, and is thought to help reduce bacterial infections and boost immune function. Before therapy begins, plasma donations are tested for known blood-borne pathogens, then pooled and processed to obtain concentrated IgG samples. Infusions can be administered in three different forms: intravenously (IVIg), subcutaneously (SCIg), and intramuscularly (IMIg).

The administration of intravenous immunoglobulins requires the insertion of a cannula or needle in a vein, usually in the arms or hands. Because a highly concentrated product is used, IVIg infusions take place every three to four weeks. Subcutaneous infusions slowly release the Ig serum underneath the skin, again through a needle, and take place every week. Intramuscular infusions are no longer widely used, as they can be painful and are more likely to cause reactions.

People often experience adverse side effects from immunoglobulin infusions, including:

• swelling at the insertion site (common in SCIG)
• chills
• headache
• nausea (common in IVIG)
• fatigue (common in IVIG)
• muscle aches and pain, or joint pain
• fever (common in IVIG and rare in SCIG)
• hives (rare)
• thrombotic events (rare)
• aseptic meningitis (rare, more common in people with SLE)
• anaphylactic shock (very rare)

In addition to Ig replacement therapy, treatment may also involve immune suppressants to control autoimmune symptoms of the disease and high-dose steroids like corticosteroids. In some cases, antibiotics are used to fight chronic lung disease resulting from CVID. The outlook for people varies greatly depending on their level of lung and other organ damage prior to diagnosis and treatment.

Epidemiology

CVID has an estimated prevalence of about 1:50,000 in Caucasians. The disease seems to be less prevalent among Asians and African Americans. Males and females are equally affected; however, among children, boys predominate. A recent study of people in Europe with primary immunodeficiencies found that 30% had CVID as opposed to a different immunodeficiency. 10–25% of people inherit the disease, typically through autosomal-dominant inheritance. Given the rarity of the disease, it is not yet possible to generalize about its prevalence among ethnic and racial groups. CVID shortens the lifespan, but no study currently has a median age recorded. One study suggests the median age of death for men and women is 42 and 44 years old, respectively, but most patients involved in the study are still alive. Those people with accompanying disorders had the worst prognosis (50% survival 33 years after diagnosis), and those with only CVID-caused frequent infections had the longest survival rates, with another study stating a life expectancy almost equaling that of the general UK population. Additionally, people with CVID with one or more noninfectious complications have an 11 times higher risk of death as compared to people with only infections.

History

Immunodeficiencies comprise many diseases and are genetic defects affecting the immune system. There are roughly 150 immunodeficiencies spanning over 120 genetic defects. Charles Janeway Sr. is generally credited with the first description of a case of CVID in 1953. The case involved a 39-year-old who had recurrent infections, bronchiectasis, and meningitis. CVID has since emerged as the predominant class of primary antibody deficiencies. It is thought to affect between 1 in 25,000 to 1 in 50,000 people worldwide. Though described in 1953, there was no standard definition for CVID until the 1990s, which caused widespread confusion during diagnosis. During the 1990s, the European Society for Immunodeficiency (ESID) and Pan-American Group for Immunodeficiency (PAGID) developed diagnostic criteria for the disease, including the minimum age of diagnosis and the need to exclude other conditions. Since publication in 1999, some criteria have been changed, such as increasing the minimum age of diagnosis.

Research

Current research is aimed at studying large cohorts of people with CVID in an attempt to better understand the age of onset as well as the mechanism, genetic factors, and progression of the disease.

Funding for research in the US is provided by the National Institutes of Health. Key research in the UK was previously funded by the Primary Immunodeficiency Association (PiA) until its closure in January 2012, and funding is raised through the annual Jeans for Genes campaign. Current efforts are aimed at studying the following:

• Causes of complications. Little is known about why such diverse complications arise during treatment.
• Underlying genetic factors. Though many polymorphisms and mutations have been identified, their respective roles in CVID development are poorly understood and not represented in all people with CVID.
• Finding new ways to study CVID. Given that CVID arises from more than one gene, gene knock-out methods are unlikely to be helpful. It is necessary to seek out disease-related polymorphisms by screening large populations of people with CVID, but this is challenging given the rarity of the disease.

References

1. ^ Chapel H, Cunningham-Rundles C (June 1, 2009). "Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions". British Journal of Haematology. 145 (6): 709–727. doi:10.1111/j.1365-2141.2009.07669.x. ISSN 1365-2141. PMC 2718064. PMID 19344423.
2. ^ "Common Variable Immune Deficiency". Genetics Home Reference. Retrieved February 8, 2016.
3. Cunningham-Rundles, C. Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults. In: UpToDate, Notarangelo, LD, Feldweg, AM (Eds), UpToDate, Waltham, MA, 2020. Retrieved April 8, 2020.
4. Herriot R, Sewell WA (2008). "Antibody deficiency". Journal of Clinical Pathology. 61 (9): 994–1000. doi:10.1136/jcp.2007.051177. PMID 18755724. S2CID 25106807.
5. ^ "Common Variable Immune Deficiency". NORD (National Organization for Rare Disorders). Retrieved November 18, 2021.
6. Zainaldain H, Rizvi FS, Rafiemanesh H, Alizadeh M, Jamee M, Mohammadi S, Kiaee F, Mohammadi H, Babaie F, Yazdani R, Abolhassani H, Aghamohammadi A, Azizi G (July 15, 2020). "Infectious Complications Reporting in Common Variable Immunodeficiency: A Systematic Review and Meta-analysis". Oman Medical Journal. 35 (4): e157. doi:10.5001/omj.2020.64. PMC 7417520. PMID 32802416.
7. ^ Andersen I, Jørgensen S (January 2, 2022). "Gut inflammation in CVID: causes and consequences". Expert Review of Clinical Immunology. 18 (1): 31–45. doi:10.1080/1744666X.2021.2008241. ISSN 1744-666X. PMID 34978241.
8. ^ Rizvi FS, Zainaldain H, Rafiemanesh H, Jamee M, Hossein-Khannazer N, Hamedifar H, Sabzevari A, Yazdani R, Abolhassani H, Aghamohammadi A, Azizi G (December 1, 2020). "Autoimmunity in common variable immunodeficiency: a systematic review and meta-analysis". Expert Review of Clinical Immunology. 16 (12): 1227–1235. doi:10.1080/1744666X.2021.1850272. ISSN 1744-666X. PMID 33203275. S2CID 227037374.
9. Kiaee F, Azizi G, Rafiemanesh H, Zainaldain H, Sadaat Rizvi F, Alizadeh M, Jamee M, Mohammadi S, Habibi S, Sharifi L, Jadidi-Niaragh F, Haghi S, Yazdani R, Abolhassani H, Aghamohammadi A (October 3, 2019). "Malignancy in common variable immunodeficiency: a systematic review and meta-analysis". Expert Review of Clinical Immunology. 15 (10): 1105–1113. doi:10.1080/1744666X.2019.1658523. ISSN 1744-666X. PMID 31452405. S2CID 201759130.
10. Giannobile J, Kapoor P, Brown E, Schroeder Jr H (February 2009). "(1) CVID Patients with HLA∗B8 or ∗B44 Have Higher Numbers of Class Switched Memory B cell Numbers than CVID Patients Without ∗B8 or ∗B44". Journal of Allergy and Clinical Immunology. 123 (2): S11. doi:10.1016/j.jaci.2008.12.055. ISSN 0091-6749.
11. Sanger, David E. "An Investigation of Coping and Psychosocial Functioning in Persons with Common Variable Immunodeficiency (CVID)" Archived July 28, 2003, at archive.today, Barts and The London NHS Trust, 2003, accessed August 7, 2011.
12. "PatientsLikeMe - Symptoms". www.patientslikeme.com. Archived from the original on April 14, 2018. Retrieved April 14, 2018.
13. ^ Park MA, Ti JT, Hagan JB, Maddox DE, Abraham RS (2008). "Common variable immunodeficiency: a new look at an old disease". The Lancet. 372 (9637): 9–15. doi:10.1016/s0140-6736(08)61199-x. PMID 18692715. S2CID 205951889.
14. Salzer U, Neumann C, Thiel J, et al. (2008). "Screening of functional and positional candidate genes in families with common variable immunodeficiency". BMC Immunol. 9 (1): 3. doi:10.1186/1471-2172-9-3. PMC 2268914. PMID 18254984.
15. Blanco-Quirós A, Solís-Sánchez P, Garrote-Adrados JA, Arranz-Sanz E (2006). "Common variable immunodeficiency. Old questions are getting clearer". Allergol Immunopathol (Madr). 34 (6): 263–75. doi:10.1157/13095875. hdl:10261/71519. PMID 17173844. S2CID 6843755. Archived from the original on May 21, 2009. Retrieved March 1, 2008.
16. O Olerup O, Smith CI, Björkander J, Hammarström L (November 15, 1992). "Shared HLA class II-associated genetic susceptibility and resistance, related to the HLA-DQB1 gene, in IgA deficiency and common variable immunodeficiency". PNAS. 89 (22): 10653–10657. Bibcode:1992PNAS...8910653O. doi:10.1073/pnas.89.22.10653. PMC 50399. PMID 1438261.
17. Chen K, Emily M. Coonrod, Attila Kumánovics, Zechariah F. Franks, Jacob D. Durtschi, Rebecca L. Margraf, Wilfred Wu, Nahla M. Heikal, Nancy H. Augustine, Perry G. Ridge, Harry R. Hill, Lynn B. Jorde, Andrew S. Weyrich, Guy A. Zimmerman, Adi V. Gundlapalli, John F. Bohnsack, Karl V. Voelkerding (October 17, 2013). "Germline Mutations in NFKB2 Implicate the Noncanonical NF-κB Pathway in the Pathogenesis of Common Variable Immunodeficiency". The American Journal of Human Genetics. 93 (5): 812–24. doi:10.1016/j.ajhg.2013.09.009. PMC 3824125. PMID 24140114.
18. ^ Peng XP, Caballero-Oteyza A, Grimbacher B (January 24, 2023). "Common Variable Immunodeficiency: More Pathways than Roads to Rome". Annual Review of Pathology: Mechanisms of Disease. 18 (1): 283–310. doi:10.1146/annurev-pathmechdis-031521-024229. ISSN 1553-4006. PMID 36266261.
19. ^ Yazdani R, Habibi S, Sharifi L, Azizi G, Abolhassani H, Olbrich P, Aghamohammadi A (February 20, 2020). "Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Classification, and Management". Journal of Investigational Allergology and Clinical Immunology. 30 (1): 14–34. doi:10.18176/jiaci.0388. PMID 30741636.
20. Amato G, Vita F, Quattrocchi P, Minciullo PL, Pioggia G, Gangemi S (October 16, 2020). "Involvement of miR-142 and miR-155 in Non-Infectious Complications of CVID". Molecules. 25 (20): 4760. doi:10.3390/molecules25204760. ISSN 1420-3049. PMC 7587593. PMID 33081305.
21. Bonilla FA, Geha RS (2009). "Common Variable Immunodeficiency". Pediatric Research. 65 (5): 13R–19R. doi:10.1203/pdr.0b013e31819dbf88. PMID 19190529. S2CID 9361175.
22. ^ Chapel H, Cunningham-Rundles C (2009). "Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions". British Journal of Haematology. 145 (6): 709–727. doi:10.1111/j.1365-2141.2009.07669.x. PMC 2718064. PMID 19344423.
23. ^ Abbott JK, Gelfand EW (2015). "Common Variable Immunodeficiency: Diagnosis, Management, and Treatment". Immunol Allergy Clin N Am. 35 (4): 637–658. doi:10.1016/j.iac.2015.07.009. PMID 26454311.
24. ^ Resnick ES, Cunningham-Rundles C (2012). "The many faces of the clinical picture of common variable immune deficiency". Current Opinion in Allergy and Clinical Immunology. 12 (6): 595–601. doi:10.1097/aci.0b013e32835914b9. PMID 23026770. S2CID 205435779.
25. "Primary immunodeficiency". Mayo Clinic. Retrieved February 17, 2016.
26. Pourpak Z, Aghamohammadi A, Sedighipour L, et al. (2006). "Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency". J Microbiol Immunol Infect. 39 (2): 114–20. PMID 16604243. Archived from the original (abstract) on September 29, 2008. Retrieved March 1, 2008.
27. Schwartz RA, Modak R, Modak P. "Common Variable Immunodeficiency Treatment and Management". Medscape. Retrieved February 17, 2016.
28. "Common Variable Immune Deficiency". Immune Deficiency Foundation. Retrieved February 16, 2016.
29. Common Variable Immunodeficiency : Article by Robert A Schwartz at eMedicine
30. Janeway CA, Apt L, Gitlin D (1953). "Agammaglobulinemia". Trans Assoc Am Physicians. 66: 200–2. PMID 13136263.
31. "Archived copy". Archived from the original on September 13, 2012. Retrieved October 26, 2012.{{cite web}}: CS1 maint: archived copy as title (link)

• Moris G., Garcia-Monco JC (1999). "The Challenge of Drug-Induced Aseptic Meningitis". Archives of Internal Medicine. 159 (11): 1185–1194. doi:10.1001/archinte.159.11.1185. PMID 10371226. (IVIG and Aseptic Meningitis, association with SLE)

External links

• GeneReviews/NCBI/NIH/UW entry on Common Variable Immune Deficiency Overview Archived June 10, 2010, at the Wayback Machine

• Biology
• Medicine

• Genetic diseases and disorders
• Noninfectious immunodeficiency-related cutaneous conditions
• Predominantly antibody deficiencies